Entrada TherapeuticsTRDA
About: Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Employees: 183
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
596% more call options, than puts
Call options by funds: $717K | Put options by funds: $103K
87% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 23
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
16% more capital invested
Capital invested by funds: $481M [Q3] → $559M (+$78.2M) [Q4]
5.52% more ownership
Funds ownership: 80.91% [Q3] → 86.43% (+5.52%) [Q4]
5% more funds holding
Funds holding: 97 [Q3] → 102 (+5) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 29% 1-year accuracy 95 / 331 met price target | 130%upside $20 | Buy Reiterated | 31 Mar 2025 |
Financial journalist opinion









